Sucampo Pharmaceuticals (SCMP) -8.4% premarket after announcing Friday the FDA extended by three months its review of the company's Amitiza drug to treat opioid-induced constipation in patients with chronic, non-cancer pain. The FDA decides to extend the goal date to provide time for a full review of supportive analyses it had requested.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs